Company profile
BELITE BIO, INC
NASDAQ:BLTEBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TINLAREBANT | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06388083 | phase2_3 | active_not_recruiting | 2024-07-31 | 2028-02-01 | Belite Bio, Inc | A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease |
| NCT05244304 | phase3 | completed | 2022-03-28 | 2025-08-04 | Belite Bio, Inc | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease |
| NCT05949593 | phase3 | active_not_recruiting | 2023-07-27 | 2027-06-30 | Belite Bio, Inc | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy |
| NCT04005807 | phase1 | completed | 2019-07-19 | 2019-12-20 | Belite Bio, Inc | Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults |
FDA applications (0)
No records yet.